← All science articles

· 2 min read

Defibrotide Dampens Monocyte Free-Radical Output, Hinting at Antithrombotic Mechanism

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Cirillo and colleagues, writing in Haemostasis in 1991, studied how defibrotide, a drug made from polydeoxyribonucleotides (chains of DNA building blocks), affects immune cells involved in blood clotting. This is a laboratory study, not a treatment trial: the researchers took monocytes, a type of white blood cell, from 7 healthy volunteers and exposed them to the drug in a dish.

At high concentrations (40 micrograms per milliliter), defibrotide barely changed the cells' clot-promoting activity or their production of superoxide anion, a reactive oxygen molecule, when triggered by a compound called zymosan. But at lower concentrations closer to what the body would see during actual drug dosing (5 to 20 micrograms per milliliter), defibrotide reduced superoxide generation in a dose-dependent way when the cells were stimulated with other triggers, FMLP or calcium ionophore A23187. The effect built up over time, reaching more than 30% suppression after 20 hours of exposure, and did not depend much on extracellular calcium levels.

The authors propose this free-radical-dampening effect as one possible explanation for how defibrotide works against clot formation. Because this is a cell-culture study in cells from a small group of healthy subjects, it cannot show whether the same effect occurs in the body or affects clinical outcomes.

Our reflection

This 1991 paper belongs to the decades of basic research into polydeoxyribonucleotide-derived compounds that preceded today's interest in PDRN for skin and tissue applications. It documents one of the biological mechanisms, effects on immune cell activity, that researchers have long tried to pin down for this class of molecules. At Havdis, we see such early mechanistic work as part of the scientific groundwork the field continues to build on, even though the gap to current PDRN applications remains wide.

Source

Cirillo F, Margaglione M, Vecchione G, Ames PR, Coppola A, Grandone E et al. (1991). Haemostasis.

Read the paper on PubMedDOI: 10.1159/000216211

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.